200 related articles for article (PubMed ID: 30027852)
21. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C.
Chiu HY; Chen CH; Wu MS; Cheng YP; Tsai TF
Br J Dermatol; 2013 Dec; 169(6):1295-303. PubMed ID: 23746170
[TBL] [Abstract][Full Text] [Related]
22. Ustekinumab.
Weber J; Keam SJ
BioDrugs; 2009; 23(1):53-61. PubMed ID: 19344192
[TBL] [Abstract][Full Text] [Related]
23. Development of bullous pemphigoid during treatment of psoriatic onycho-pachydermo periostitis with ustekinumab.
Nakayama C; Fujita Y; Watanabe M; Shimizu H
J Dermatol; 2015 Oct; 42(10):996-8. PubMed ID: 26010891
[TBL] [Abstract][Full Text] [Related]
24. Onset of frontal fibrosing alopecia during inhibition of Th1/17 Pathways with ustekinumab.
King AD; Lam L; Goh C
Dermatol Online J; 2019 Jul; 25(7):. PubMed ID: 31450280
[TBL] [Abstract][Full Text] [Related]
25. Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a.
Leonardi CL
Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S74-7. PubMed ID: 27551698
[TBL] [Abstract][Full Text] [Related]
26. Development of hidradenitis suppurativa in a patient treated with ustekinumab for her psoriasis: A potential paradoxical reaction?
Gkini MA; Bewley AP
Dermatol Ther; 2018 Nov; 31(6):e12742. PubMed ID: 30221819
[No Abstract] [Full Text] [Related]
27. Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis.
Zhou H; Hu C; Zhu Y; Lu M; Liao S; Yeilding N; Davis HM
J Clin Pharmacol; 2010 Mar; 50(3):257-67. PubMed ID: 19934030
[TBL] [Abstract][Full Text] [Related]
28. Translating the Science of Psoriasis.
Gordon KB
Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S64. PubMed ID: 27526392
[TBL] [Abstract][Full Text] [Related]
29. Long-term therapy with ustekinumab for psoriasis in a patient with a history of malignant melanoma.
Gkalpakiotis S; Arenberger P; Fridman M; Arenbergerova M
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28730674
[No Abstract] [Full Text] [Related]
30. Safety of systemic therapies in the treatment of psoriasis with concomitant cirrhosis: a retrospective study.
Blaszczak AM; Dunaway S; Ali Alikhan M; Kelly S; Levin D; Kaffenberger J
Int J Dermatol; 2019 Nov; 58(11):e228-e229. PubMed ID: 31334835
[No Abstract] [Full Text] [Related]
31. Therapeutic Efficacy of Interleukin 12/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status.
Arakawa A; Ruzicka T; Prinz JC
JAMA Dermatol; 2016 Jul; 152(7):825-8. PubMed ID: 27096382
[TBL] [Abstract][Full Text] [Related]
32. Ustekinumab exposure during conception and pregnancy in patients with chronic plaque psoriasis: a case series of 10 pregnancies.
Watson N; Wu K; Farr P; Reynolds NJ; Hampton PJ
Br J Dermatol; 2019 Jan; 180(1):195-196. PubMed ID: 30101563
[No Abstract] [Full Text] [Related]
33. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up.
Langley RG; Lebwohl M; Krueger GG; Szapary PO; Wasfi Y; Chan D; Hsu MC; You Y; Poulin Y; Korman N; Prinz JC; Reich K;
Br J Dermatol; 2015; 172(5):1371-83. PubMed ID: 25307931
[TBL] [Abstract][Full Text] [Related]
34. Sarcoid- like Phenomenon - ustekinumab induced granulomatous reaction mimicking diffuse metastatic disease: a case report and review of the literature.
Gad MM; Bazarbashi N; Kaur M; Gupta A
J Med Case Rep; 2019 Jul; 13(1):257. PubMed ID: 31358038
[TBL] [Abstract][Full Text] [Related]
35. Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study.
Gniadecki R; Bang B; Sand C
Br J Dermatol; 2016 May; 174(5):1145-6. PubMed ID: 26522308
[No Abstract] [Full Text] [Related]
36. Ocular toxoplasmosis in a patient treated with ustekinumab for psoriasis.
Javadzadeh S; Gkini MA; Panos GD; Adewoyin T; Bewley A
Clin Exp Dermatol; 2020 Aug; 45(6):802-804. PubMed ID: 32212270
[No Abstract] [Full Text] [Related]
37. Association between clinical factors and dose modification strategies in the treatment with ustekinumab for moderate-to-severe plaque psoriasis.
Romero-Jimenez RM; Escudero-Vilaplana V; Baniandres Rodriguez O; García Martín E; Mateos Mayo A; Sanjurjo Saez M
J Dermatolog Treat; 2018 Dec; 29(8):792-796. PubMed ID: 29676189
[TBL] [Abstract][Full Text] [Related]
38. Ustekinumab treatment for psoriasis in 119 patients maintained on therapy for a minimum of one year: a review.
Wilder EG; Patel M; Hebeler K; Menter A
J Drugs Dermatol; 2014 Aug; 13(8):905-10. PubMed ID: 25116966
[TBL] [Abstract][Full Text] [Related]
39. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
Khanna R; Preiss JC; MacDonald JK; Timmer A
Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
[TBL] [Abstract][Full Text] [Related]
40. Efalizumab-induced lupus-like syndrome.
Durox H; Sparsa A; Loustaud-Ratti V; Prey S; Gondran G; Manea P; Vidal E; Bedane C
Acta Derm Venereol; 2008; 88(3):270-1. PubMed ID: 18480928
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
